Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
60
The interventional product is rimegepant ODT 75 mg. Rimegepant 75mg ODT will be given 2 hours prior to a trigger exposure for exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours rimegepant will be dosed 2 hours prior to trigger exposure. For weekend or let down headache and changes in sleep pattern, rimegepant will be dosed the night before. The maximum dose in a 24-hour period is 75mg.
MedStar Health: Neurology at McLean
McLean, Virginia, United States
RECRUITINGPercentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity
Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity occurs within 24 hours
Time frame: 24 hour post dose
Percentage of preemptive treatments with rimegepant
Percentage of preemptive treatments with rimegepant in which migraine occurs within 24 hours * Percentage of preemptive treatments with rimegepant that require rescue medication within 24 hours * Percentage of preemptive treatments with rimegepant that result in acute medication use within 48 hours of treatment
Time frame: 24 hour, 48 hour post dose
Patient satisfaction with preemptive treatment with rimegepant
Patient satisfaction with preemptive rimegepant treatment will be assessed in the case report form using a Likert scale
Time frame: At the end of the study completion( 2 month after enrollment)
The effect of preemptive treatment with rimegepant on Patient Global Impression of Change (PGIC)
The effect of preemptive treatment with rimegepant on Patient Global Impression of Change (PGIC) using a graded scale of 1-7.
Time frame: At the end of study completion( 2 months after enrollement)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.